Literature DB >> 9614872

Release of viral glycoproteins during Ebola virus infection.

V E Volchkov1, V A Volchkova, W Slenczka, H D Klenk, H Feldmann.   

Abstract

Maturation and release of the Ebola virus glycoprotein GP were studied in cells infected with either Ebola or recombinant vaccinia viruses. Significant amounts of GP were found in the culture medium in nonvirion forms. The major form represented the large subunit GP1 that was shed after release of its disulfide linkage to the smaller transmembrane subunit GP2. The minor form were intact GP1,2 complexes incorporated into virosomes. Vector-expressed GP formed spikes morphologically indistinguishable from spikes on virus particles, indicating that spike assembly is independent of other viral proteins. Analysis of a truncation mutant revealed an early and almost complete release of GP1,2 molecules, showing that membrane anchoring is mediated by the carboxy-terminal hydrophobic domain of GP2. We have also compared wild-type virus which requires transcriptional editing for synthesis of full-length GP with a variant that does not depend on editing. Both viruses released comparable amounts of GP1, but the variant expressed only minute amounts of the small, soluble GP which is the expression product of nonedited mRNA species of the GP gene. The abundant shedding of soluble GP1 may play an important role in the immunopathology of Ebola hemorrhagic fever in experimentally and naturally infected hosts.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9614872     DOI: 10.1006/viro.1998.9143

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  36 in total

1.  Ebola virus can be effectively neutralized by antibody produced in natural human infection.

Authors:  T Maruyama; L L Rodriguez; P B Jahrling; A Sanchez; A S Khan; S T Nichol; C J Peters; P W Parren; D R Burton
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Sorting of Marburg virus surface protein and virus release take place at opposite surfaces of infected polarized epithelial cells.

Authors:  C Sänger; E Mühlberger; E Ryabchikova; L Kolesnikova; H D Klenk; S Becker
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  Ebola virus VP40-induced particle formation and association with the lipid bilayer.

Authors:  L D Jasenosky; G Neumann; I Lukashevich; Y Kawaoka
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding.

Authors:  R N Harty; M E Brown; G Wang; J Huibregtse; F P Hayes
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

5.  Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry.

Authors:  Graham Simmons; Jacqueline D Reeves; Andrew J Rennekamp; Sean M Amberg; Andrew J Piefer; Paul Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-09       Impact factor: 11.205

6.  Unconventional secretion of Ebola virus matrix protein VP40.

Authors:  Olivier Reynard; St Patrick Reid; Audrey Page; Mathieu Mateo; Nathalie Alazard-Dany; Hervé Raoul; Christopher F Basler; Viktor E Volchkov
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

7.  Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice.

Authors:  Wenfang Li; Ling Ye; Ricardo Carrion; Gopi S Mohan; Jerritt Nunneley; Hilary Staples; Anysha Ticer; Jean L Patterson; Richard W Compans; Chinglai Yang
Journal:  J Infect Dis       Date:  2015-04-14       Impact factor: 5.226

8.  Ebola virus VP35-VP40 interaction is sufficient for packaging 3E-5E minigenome RNA into virus-like particles.

Authors:  Reed F Johnson; Sarah E McCarthy; Peter J Godlewski; Ronald N Harty
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

9.  Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda x light chain.

Authors:  Jeffrey E Lee; Ana Kuehne; Dafna M Abelson; Marnie L Fusco; Mary Kate Hart; Erica Ollmann Saphire
Journal:  J Mol Biol       Date:  2007-10-16       Impact factor: 5.469

10.  Pathophysiology of Ebola Virus Infection: Current Challenges and Future Hopes.

Authors:  Andrea Rivera; Ilhem Messaoudi
Journal:  ACS Infect Dis       Date:  2015-03-30       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.